PT1027053E - Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus - Google Patents

Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus

Info

Publication number
PT1027053E
PT1027053E PT98952186T PT98952186T PT1027053E PT 1027053 E PT1027053 E PT 1027053E PT 98952186 T PT98952186 T PT 98952186T PT 98952186 T PT98952186 T PT 98952186T PT 1027053 E PT1027053 E PT 1027053E
Authority
PT
Portugal
Prior art keywords
tacrolimus
administration
patient
cyclosporin
pps
Prior art date
Application number
PT98952186T
Other languages
English (en)
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Us Health
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Ivax Research Inc filed Critical Us Health
Publication of PT1027053E publication Critical patent/PT1027053E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
PT98952186T 1997-10-09 1998-10-09 Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus PT1027053E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09

Publications (1)

Publication Number Publication Date
PT1027053E true PT1027053E (pt) 2004-09-30

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98952186T PT1027053E (pt) 1997-10-09 1998-10-09 Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus

Country Status (23)

Country Link
US (1) US6187745B1 (pt)
EP (1) EP1027053B1 (pt)
JP (1) JP2001519392A (pt)
KR (1) KR100515196B1 (pt)
CN (1) CN1154492C (pt)
AT (1) ATE269098T1 (pt)
AU (1) AU748495B2 (pt)
BR (1) BR9813860A (pt)
CA (1) CA2304374A1 (pt)
CZ (1) CZ297440B6 (pt)
DE (1) DE69824619T2 (pt)
DK (1) DK1027053T3 (pt)
ES (1) ES2221714T3 (pt)
HU (1) HUP0003904A3 (pt)
IL (1) IL135235A0 (pt)
NO (1) NO20001828L (pt)
NZ (1) NZ503493A (pt)
PL (1) PL191993B1 (pt)
PT (1) PT1027053E (pt)
RU (1) RU2191020C2 (pt)
SK (1) SK285332B6 (pt)
UA (1) UA65587C2 (pt)
WO (1) WO1999018961A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052867A1 (en) * 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
HRP20040354B1 (en) * 2001-10-19 2012-10-31 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
MXPA04010170A (es) * 2002-04-16 2005-02-03 Fujisawa Pharmaceutical Co Medicamento para prevenir y/o tratar el rechazo cronico.
PL1748781T3 (pl) 2004-05-27 2013-05-31 Baxter Int Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
WO2010020423A2 (en) 2008-08-22 2010-02-25 Baxter Healthcare S.A. Methods for treating bleeding disorders
AU2011205271B2 (en) 2010-01-14 2014-01-30 Baxalta GmbH Methods and compositions for treating bleeding disorders
US8871741B2 (en) * 2010-01-15 2014-10-28 Icahn School Of Medicine At Mount Sinai Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP2734213B1 (en) 2011-07-19 2018-06-06 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013052380A2 (en) 2011-10-05 2013-04-11 Allergan, Inc. Compositions for enhancing nail health
DK2885642T3 (da) 2012-08-14 2019-07-29 Baxalta GmbH Fremgangsmåder og systemer til screening af sammensætninger omfattende ikke-antikoagulerende sulfaterede polysaccharider
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180011840A (ko) * 2015-06-12 2018-02-02 비샬 자조디아 스와티 방광 출구 폐쇄 및/또는 하부 요로 증상의 치료에서 사용하기 위한 펜토산폴리설페이트나트륨을 포함하는 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB9116836D0 (en) * 1991-08-05 1991-09-18 Sandoz Ltd Organic compounds
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) * 1992-04-14 1995-01-27 Северо-Кавказский горно-металлургический институт Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
DE69824619D1 (de) 2004-07-22
CA2304374A1 (en) 1999-04-22
HUP0003904A3 (en) 2006-06-28
KR20010030749A (ko) 2001-04-16
HUP0003904A1 (hu) 2001-08-28
AU9794398A (en) 1999-05-03
ES2221714T3 (es) 2005-01-01
ATE269098T1 (de) 2004-07-15
NO20001828L (no) 2000-05-15
KR100515196B1 (ko) 2005-09-16
CN1275080A (zh) 2000-11-29
BR9813860A (pt) 2001-03-20
NO20001828D0 (no) 2000-04-07
SK4672000A3 (en) 2001-09-11
PL339774A1 (en) 2001-01-02
DK1027053T3 (da) 2004-09-06
EP1027053A4 (en) 2002-05-22
HK1026845A1 (en) 2000-12-29
EP1027053A1 (en) 2000-08-16
JP2001519392A (ja) 2001-10-23
US6187745B1 (en) 2001-02-13
CZ20001274A3 (cs) 2001-12-12
PL191993B1 (pl) 2006-08-31
DE69824619T2 (de) 2005-06-23
EP1027053B1 (en) 2004-06-16
RU2191020C2 (ru) 2002-10-20
IL135235A0 (en) 2001-05-20
WO1999018961A1 (en) 1999-04-22
NZ503493A (en) 2001-11-30
SK285332B6 (sk) 2006-11-03
UA65587C2 (en) 2004-04-15
AU748495B2 (en) 2002-06-06
CN1154492C (zh) 2004-06-23
CZ297440B6 (cs) 2006-12-13

Similar Documents

Publication Publication Date Title
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
PL350313A1 (en) Apomorphine and sildenafil composition
JP2002523370A5 (pt)
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
US4425363A (en) Treatment of tardive dyskinesia in mammals
CA2274510A1 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
MY124465A (en) Reduction of infarct volume using citicoline
CA2537748A1 (en) Use of telmisartan for the prevention of vascular headache
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
BE1002255A5 (fr) Medicaments.
RU2449796C9 (ru) Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
MX9800809A (es) Procedimiento para preparar formas de dosis solidas de dosis muy bajas del farmaco.
CN107519176A (zh) 防治运动病、梅尼埃病的药物及莫扎伐普坦的医药用途
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
KR830008678A (ko) 진통 조성물
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
JPH07188040A (ja) 鼻炎治療用組成物
JPH0296521A (ja) 免疫性疾患治療剤
Di Prima et al. Clinical and bacteriological evaluation of ofloxacin in 20 cases of skin infection.